MAM
COLL icon

Martingale Asset Management’s Collegium Pharmaceutical COLL Stock Holding History

Martingale Asset Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2M Buy
55,155
+6,601
+14% +$226K 0.05% 393
2026
Q1 		$1.61M Buy
48,554
+10,401
+27% +$440K 0.04% 389
2025
Q4 		$1.77M Buy
38,153
+6,690
+21% +$280K 0.04% 348
2025
Q3 		$1.1M Buy
31,463
+18,453
+142% +$641K 0.03% 453
2025
Q2 		$385K Buy
+13,010
New +$371K 0.01% 664
2025
Q1 		– Sell
-29,087
Closed -$833K – 783
2024
Q4 		$833K Sell
29,087
-10,700
-27% -$354K 0.02% 517
2024
Q3 		$1.54M Buy
39,787
+291
+0.7% +$10.4K 0.04% 371
2024
Q2 		$1.27M Sell
39,496
-100
-0.3% -$3.47K 0.03% 397
2024
Q1 		$1.54M Buy
39,596
+107
+0.3% +$3.74K 0.03% 358
2023
Q4 		$1.22M Buy
39,489
+464
+1% +$11.6K 0.02% 408
2023
Q3 		$872K Buy
39,025
+400
+1% +$9.12K 0.02% 475
2023
Q2 		$830K Buy
38,625
+4,401
+13% +$99.9K 0.02% 494
2023
Q1 		$821K Buy
34,224
+6,056
+21% +$161K 0.02% 500
2022
Q4 		$653K Buy
28,168
+3,855
+16% +$77.7K 0.01% 571
2022
Q3 		$390K Buy
24,313
+7,887
+48% +$139K 0.01% 667
2022
Q2 		$292K Buy
16,426
+393
+2% +$6.61K 0.01% 737
2022
Q1 		$327K Buy
+16,033
New +$303K ﹤0.01% 713
2021
Q3 		– Sell
-10,014
Closed -$237K – 863
2021
Q2 		$237K Sell
10,014
-6,616
-40% -$153K ﹤0.01% 770
2021
Q1 		$396K Sell
16,630
-300
-2% -$7.13K ﹤0.01% 675
2020
Q4 		$341K Sell
16,930
-59,288
-78% -$1.16M ﹤0.01% 715
2020
Q3 		$1.59M Buy
76,218
+44,914
+143% +$811K 0.02% 489
2020
Q2 		$548K Sell
31,304
-33
-0.1% -$646 0.01% 860
2020
Q1 		$512K Buy
+31,337
New +$647K 0.01% 809
2019
Q4 		– Sell
-95,965
Closed -$1.1M – 973
2019
Q3 		$1.1M Buy
+95,965
New +$1.1M 0.01% 747
2019
Q2 		– Sell
-58,544
Closed -$888K – 1015
2019
Q1 		$888K Buy
58,544
+711
+1% +$11.4K 0.01% 805
2018
Q4 		$994K Buy
+57,833
New +$989K 0.01% 721

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Martingale Asset Management's COLL Position: Q2 2026 in Review

Martingale Asset Management increased its Collegium Pharmaceutical (COLL) stake by 14% in Q2 2026, buying an estimated $226K and bringing the position to 55,155 shares worth $2M. The position accounts for 0.05% of the portfolio, ranked #393.

Martingale Asset Management first reported a position in COLL in Q4 2018 and has held it in 26 quarters since. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Martingale Asset Management held 55,155 shares of Collegium Pharmaceutical worth $2M as of Q2 2026.
  • Martingale Asset Management bought 6,601 Collegium Pharmaceutical shares in Q2 2026, an estimated $226K.
  • Collegium Pharmaceutical made up 0.05% of Martingale Asset Management's portfolio in Q2 2026, its #393 holding.
  • Martingale Asset Management first reported a position in Collegium Pharmaceutical in Q4 2018 and has held it in 26 quarters since.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.